Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 2/20 | 0.49 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.49 |
| ▸ | ALK | Q9UM73 | 3/20 | 0.45 |
| ▸ | PTK6 | Q13882 | 6/20 | 0.44 |
| ▸ | EGFR | P00533 | 4/20 | 0.44 |
| ▸ | IGF1R | P08069 | 3/20 | 0.44 |
| ▸ | UTS2R | Q9UKP6 | 2/20 | 0.42 |
| ▸ | IP6K1 | Q92551 | 1/20 | 0.40 |
| ▸ | IP6K3 | Q96PC2 | 1/20 | 0.40 |
| ▸ | IP6K2 | Q9UHH9 | 1/20 | 0.40 |
| ▸ | PPARG | P37231 | 1/20 | 0.40 |
| ▸ | KDR | P35968 | 1/20 | 0.39 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL675879 | 0.82 | KDM5B (0.48) | — | |
| SCHEMBL675411 | 0.82 | UTS2R (0.52) | AURKAAURKBALKEGFRIGF1R | |
| SCHEMBL4958759 | 0.80 | AURKA (0.46) | AURKAAURKBALKPTK6EGFR | |
| SCHEMBL676245 | 0.79 | ALK (0.62) | AURKAAURKBALKPTK6 | |
| SCHEMBL674984 | 0.78 | UTS2R (0.44) | AURKAAURKBALKPTK6EGFR | |
| SCHEMBL677767 | 0.77 | JAK2 (0.43) | IP6K1IP6K3IP6K2PPARGKDR | |
| SCHEMBL27821849 | 0.76 | ALK (0.43) | AURKAAURKBALKPTK6EGFR | |
| SCHEMBL27821941 | 0.76 | ALK (0.46) | AURKAAURKBALKPTK6EGFR | |
| SCHEMBL31240940 | 0.76 | AURKA (0.68) | AURKAAURKBALKPTK6EGFR | |
| SCHEMBL675631 | 0.76 | AURKA (0.68) | AURKAAURKBALKPTK6EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8895744-B2 | Alfa-carboline inhibitors of NPM-ALK, RET, and Bcr-Abl | UNIVERSITA' DEGLI STUDI DI MILANO-BICOCCA (IT) | 2014-11-25 | — | — | US | disclosed |
| US-20110281862-A1 | ALFA-CARBOLINE INHIBITORS OF NPM-ALK, RET, AND BCR-ABL | UNIVERSITA' DEGLI STUDI DI MILANO - BICOCCA (IT) | 2011-11-17 | — | — | US | disclosed |
| WO-2010025872-A2 | ALFA-CARBOLINE INHIBITORS OF NPM-ALK, RET, AND BCR-ABL | UNIVERSITA' DEGLI STUDI DI MILANO-BICOCCA (IT) | 2010-03-11 | — | — | WO | disclosed |
| EP-2161271-A1 | Alpha-carboline inhibitors of NMP-ALK, RET, and Bcr-Abl | Università Degli Studi Di Milano - Bicocca (IT) | 2010-03-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110281862-A1 | ALFA-CARBOLINE INHIBITORS OF NPM-ALK, RET, AND BCR-ABL | ALK, BCR, NPM1 | AURKA 1772/4885AURKB 1300/4885ALK 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.